The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single ...

The lab of one University of Illinois researcher is receiving a hefty grant, which will be used towards cancer research. On ...

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say ...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...

Antibody-drug conjugates (ADCs) combine antibodies with cytotoxic drugs to target cancer cells while minimizing damage to ...

The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.

Bacteria-based therapies represent an exciting breakthrough in cancer treatment, harnessing their remarkable ability to ...

Shares of Aura Biosciences climbed after the company said it received positive early data for its cancer drug bel-sar. The stock rose 14% to $11.70 in early trading Friday, after hitting a new 52-week ...

Shares of Repare Therapeutics RPTX gained 8% on Monday after it announced dosing the first patient in an early-stage study ...

While the Nobel-winning genome-editing technology CRISPR holds great promise, Duke’s Center for Advanced Genomic Technologies ...

Deanna Savage founded “Savage Support," a volunteer-run organization to help others going through the rigors of breast cancer, treatment and rehabilitation.